Last updated on February 2019

Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis


Brief description of study

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Amyotrophic Lateral Sclerosis when administered for 29 days in a cross-over design

Detailed Study Description

This is a Phase 1b randomized, placebo-controlled, double-blind, crossover study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL747 in subjects with Amyotrophic Lateral Sclerosis (ALS)

Clinical Study Identifier: NCT03757351

Contact Investigators or Research Sites near you

Start Over

Melissa Leedom

CHDR
Leiden, Netherlands
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.